Compare Global Payments Inc (GPN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs TransMedics Group Inc — how do they compare? Global Payments Inc trades at $82.55 (market cap $21.46B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Global Payments Inc is far larger — about 7.8× TransMedics Group Inc's market cap, and Global Payments Inc pays a 1.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and TransMedics Group Inc for 24 Days on average.
| GPN | TMDX | |
|---|---|---|
Market Cap | $21.46B | $2.74B |
Volume | 1,482,600 | 949,331 |
Sector | Financials | Health |
52-Week High | $94.83 | $150.42 |
52-Week Low | $62.47 | $61.99 |
Typical Hold Time | 50 Days | 24 Days |
Enterprise Value | $39.60B | $3.13B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% with neutral technical signals. The stock shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net margins. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains bullish with a $102.75 price target.
Investment outlook balances growth catalysts from digital payment expansion against rising costs and competitive pressures. The 24% upside to consensus target offers potential reward, but investors must weigh debt levels increasing to 41.57% debt-to-asset ratio and projected 2026 net loss against strategic initiatives. Near-term performance hinges on Q3 earnings delivery and Genius adoption metrics.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
